Floatz logo

Exenatide

Glucose Metabolism Disease

RenJi Hospitalprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Glucose Metabolism Disease cohort.

Asset / SponsorPhaseRating
Metformin
SINA Health Education and Welfare Trust
Phase 4BBB
Retrovir
Kirby Institute
Phase 4BB
Glargine
Federico II University
Phase 4BB
Empagliflozin
SINA Health Education and Welfare Trust
Phase 4BB
Pravastatin
Kirby Institute
Phase 4BB

View all 28 →

Same molecule, other indications

Exenatide is also rated in:

type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →